Mizuho Securities Remains Bullish on Eagle Pharmaceuticals (EGRX) Despite Weak 4Q; Investors Focus on Bendeka Opportunity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Eagle Pharmaceuticals (EGRX) Misses Q4 EPS Views
February 25, 2016 6:50 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.07, $0.23 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $18.2 million versus the consensus estimate of $20.78 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... MoreTrading Radar for 2/25: Baidu (BIDU), Best Buy (BBY), Sears (SHLD), Weight Watchers (WTW) Report
February 24, 2016 2:50 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
9:00am EST
FHFA Home Price Index - no Street consensusEarnings:
AB InBev SA (NYSE: BUD) - consensus EPS $1.23
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus EPS $0.47
AMC Networks (Nasdaq:... More
